

1 **Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in**
2 **eastern Ethiopia**

3 Nega Assefa^{1,2,*}, Lemma Demissie¹, Zelalem Teklemariam¹, Joseph Oundo², Lola Madrid²,
4 Addisu Kebede³, Yadeta Dessie¹, J. Anthony G. Scott²

5 ¹ College of Health and Medical Sciences, Haramaya University, Ethiopia

6
7 ² London School of Hygiene & Tropical Medicine, UK

8
9 ³ Ethiopian Public Health Institute, Addis Ababa, Ethiopia
10

11 * corresponding author
12 Nega Assefa
13 Email: negaassefa@yahoo.com
14

15 Contact address
16 NA: negaassefa@yahoo.com
17 LDR: esraeldemiss@gmail.com
18 ZT: zelalemtmariam@yahoo.com
19 LM: lola.madrid-castillo@lshtm.ac.uk
20 JO: joseph.oundo@lshtm.ac.uk
21 YD: yad_de2005@yahoo.com
22 JAGS: anthony.scott@lshtm.ac.uk
23

24 Target Journal

25
26 Word counts
27 Abstract 245
28 Main text 2231
29
30

31 **Abstract**

32 Information on the cumulative incidence of SARS-CoV-2 in East Africa is scarce. We conducted
33 serosurveillance of anti-SARS-CoV-2 antibodies among pregnant women attending their first
34 antenatal care visit in three health facilities in eastern Ethiopia.

35 We collected data using questionnaire and a blood sample from 3,312 pregnant women between
36 April 1, 2020 and March 31, 2021 at health facilities in Haramaya, Aweday and Harar. We
37 selected 1,447 blood samples at random and assayed these for anti-SARS-CoV-2 antibodies at
38 Hararghe Health Research laboratory using WANTAI® SARS-CoV-2 Rapid Test for total
39 immunoglobulin. Temporal trends in seroprevalence were analysed with a χ^2 test for trend and
40 multivariable binomial regression.

41 Among 1,447 sera tested, 83 were positive for anti-SARS-CoV-2 antibodies giving a crude
42 seroprevalence of 5.7% (95% CI 4.6%, 7.0%). Of 160 samples tested in April-May, 2020, none
43 was seropositive; the first seropositive sample was identified in June and seroprevalence rose
44 steadily thereafter (χ^2 test for trend, $p=0.003$) reaching a peak of 11.8% in February, 2021. In the
45 multivariable model, seroprevalence was approximately 3% higher in first-trimester mothers
46 compared to later presentations, and rose by 0.75% (95% CI 0.31%, 1.20%) per month of
47 calendar time.

48 This clinical convenience sample illustrates the dynamic of the SARS-CoV-2 epidemic in young
49 adults in eastern Ethiopia; infection was rare before June 2020 but it spread in a linear fashion
50 thereafter, rather than following intermittent waves, and reached 10% by the beginning of 2021.
51 After one year of surveillance, most pregnant mothers remained susceptible.

52 **Keywords:** COVID 19, COVID-19 seroprevalence, COVID-19 among pregnant women,

53 COVID-19 in Ethiopia

54

55 **Introduction**

56 In Ethiopia, the first case of COVID-19 was reported on 13 March 2020. By the end of March
57 2021 there were 206,589 reports of COVID-19 infection and 2,865 coronavirus-related deaths. In
58 a country with an estimated population, in 2019, of 112 million this represents a cumulative
59 incidence of SARS-CoV-2 infection of only 0.2% after a full year of transmission. Many cases
60 of COVID-19 present with mild symptoms and, in Ethiopia, three quarters of PCR-positive cases
61 have no symptoms [1,2]. Access to PCR testing in Ethiopia is also sparse. Monitoring the
62 epidemic by detecting symptomatic cases is, therefore, highly insensitive. In these
63 circumstances, seroprevalence of anti-SARS-CoV-2 antibodies can provide a more accurate
64 estimator of cumulative incidence. Undertaking community serosampling during the pandemic is
65 difficult when travel and household access are constrained by control measures. Expectant
66 mothers, however, are likely to continue to seek health services throughout the pandemic and
67 they can be used as a continuously-available proxy population to estimate the cumulative
68 incidence among young adults [3-5]. In addition, serological surveillance is simple to implement
69 at ANC clinic visits because anti-SARS-CoV-2 antibodies can be assayed in the residual blood
70 volumes of routine samples collected for clinical screening for anemia and maternal infectious
71 diseases.

72 Planning and provision of health care during a major epidemic like COVID-19 pose substantial
73 logistical and clinical challenges. Information on the shape of the epidemic curve is critical to
74 inform public health responses. The dynamics of seroprevalence reflect the epidemic curve and
75 can provide an estimate of the effective reproduction number. Seroprevalence also indicates the
76 likelihood of approaching transmission control through population immunity. This study aimed

77 to assess the trend in seroprevalence of anti-SARS-CoV-2 antibodies throughout the first year of
78 the epidemic by assaying anti-SARS-CoV-2 antibodies among pregnant women attending ante-
79 natal clinic at three different health facilities in the area around Harar, eastern Ethiopia.

80 **Results**

81 **Demographic characteristics of the study participants**

82 Between April 1, 2020 and March 31, 2021 there were 3,313 first visits to the antenatal clinics;
83 1,532 (46.24%) at Hiwot Fana Hospital, 1781 (53.75%) at Aweday Health Centre and Haramaya
84 Hospital. At these, we interviewed and collected blood samples from 3,312 women. We tested a
85 random sample of 1,447 blood specimens (Table 1); 752 (52%) were from Haramaya District
86 (Aweday Health Centre and Haramaya Hospital) and 695 (48%) were from Hiwot Fana Hospital;
87 984 (68%) were urban residents (Table 1).

88 Table 1. Characteristics of 1,447 pregnant mothers attending their first antenatal care at the two
89 study areas between April 2020 and March 2021 and sampled at random for the study.

Characteristics	Haramaya District		Hiwot Fana Hospital		Total	
	n	%	n	%	n	%
Age in years						
14-19	98	13.0	74	13.5	192	13.3
20-24	341	45.4	268	35.6	588	40.7
25-29	181	24.1	219	31.6	400	27.7
30-34	110	14.6	100	14.4	210	14.5
>=35	22	2.9	35	4.9	56	3.9
Residence						
Urban	577	76.8	407	58.7	984	68.1
Rural	174	23.2	287	41.4	461	31.9

Number of children						
None	298	40.0	254	36.8	552	38.4
1-5	422	56.6	401	58.1	823	57.3
6-10	26	3.5	35	5.1	61	4.3
Trimester of visit						
First	223	29.7	143	20.6	366	25.3
Second	416	55.3	242	34.8	658	45.5
Third	113	15.0	310	44.6	423	29.2
Comorbidities						
None	750	99.7	689	99.1	1,439	99.5
At least one*	2	0.3	6	0.9	8	0.6
COVID symptoms [†]						
No	721	96.4	668	96.5	1,389	96.5
Yes	27	3.6	24	3.5	51	3.5

90

91 * chronic liver, renal, cardiovascular or ‘other’ disease

92 [†] at least one of cough, fever, headache or difficulty breathing

93

94 Among the population sample tested, the mean (SD) age was 23.9 (4.7) years and ages ranged
 95 from 15 to 45 years. The mean (SD) number of children per mother was 1.5 (1.8). The median
 96 (IQR) gestational age at the first antenatal visit was 20 (13-28) weeks. Only 51 (3.5%) had
 97 COVID-19 symptoms at the time of sampling and 8 (<1%) had a history of comorbidity, given
 98 as chronic liver, renal, cardiovascular or ‘other’ disease. Respiratory diseases, chronic
 99 neurological disease, diabetes mellitus, and cancer were not reported by any participant (Table
 100 2).

101 Table 2. Seroprevalence of Anti-SARS-CoV-2 antibodies by participant characteristics.

Characteristics	Tested	Sero- positive	Sero- prevalence	χ^2 test
-----------------	--------	-------------------	---------------------	---------------

	N	n	%	
Age in years				
14-19	192	7	3.7	p=0.19
20-24	588	42	7.1	
25-29	400	24	6.0	
30-34	210	9	4.3	
>=35	56	1	1.8	
ANC clinic				
Hiwot Fana Hospital	695	35	5.0	p=0.26
Haramaya Hospital	19	0	0.0	
Aweday Health Centre	733	48	6.6	
Residence				
Urban	984	57	5.8	p=0.91
Rural	461	26	5.6	
Number of children				
None	520	32	5.8	P=0.370
1-5	778	45	5.5	
6-10	55	6	9.8	
Trimester of visit				
First	366	31	8.5	p=0.034
Second	658	32	4.9	
Third	423	20	4.8	
Comorbidities				
None	1,439	81	5.6	p=0.019
At least one*	8	2	25.0	
COVID symptoms†				
No	1,389	82	5.9	p=0.24
Yes	51	1	2.0	

102

103 * chronic liver, renal, cardiovascular or 'other' disease


104 † at least one of cough, fever, headache or difficulty breathing

105 Seroprevalence of SARS-CoV-2 antibodies

106 Of 1,447 samples tested, 83 (5.7%, 95% CI 4.6, 7.0%) were positive for anti-SARS-CoV-2

107 antibodies. The first seropositive sample was identified on June 11, 2020, and seroprevalence

108 rose progressively thereafter, with the exception of March 2021, where it dropped sharply (χ^2 for
109 trend for the whole year, $p=0.003$; Figure 1).



110
111 Figure 1: Temporal trend of seroprevalence of anti-SARS-CoV-2 antibodies among pregnant
112 women presenting for first antenatal care in 3 ANC facilities, eastern Ethiopia, between
113 April 1, 2020 and March 31, 2021

114 Seroprevalence also varied significantly by trimester of pregnancy and co-morbidity but not by
115 clinic, residence or COVID-19 symptoms (Table 2). Given the linear growth in seroprevalence
116 (Figure 1) and better model fit based on Bayesian information criterion, we modelled prevalence

117 associations as risk differences rather than risk ratios. In a multivariable binomial regression
118 model, the prevalence difference was -3.2% (95% CI -6.7, -0.4%) and -3.0% (95% CI -6.8, -
119 0.8%) among women in their second and third trimesters, respectively, compared with those in
120 the first trimester and the prevalence difference was 0.75% (95% CI 0.31, 1.20%) per month of
121 calendar time.

122 **Discussion**

123 The study provides a simple description of the dynamic of SARS-CoV-2 epidemic in an area
124 where reliable data are extremely rare. In a population of attendees at ante-natal clinics in three
125 sites in eastern Ethiopia, antibodies against SARS-CoV-2 first appeared in June 2020 and
126 seroprevalence rose steadily month on month reaching approximately 10% at the beginning of
127 2021. Although the point estimate for March 2021 is substantially lower, the data as a whole
128 evince a strong linear trend and this single estimate is most likely to have deviated from the
129 general direction by chance. If these results are reliable, they indicate that the epidemic is
130 progressing here at a considerably lower rate than in other settings in East Africa and that the
131 greater majority of the population remains uninfected, suggesting that the epidemic is still at an
132 early stage.

133 The principal limitations of the study are the potential generalisability of the population under
134 surveillance and the validity of the serological assay employed. Pregnant women have been used
135 as an indicator population in prior pandemics, including HIV [6], but also for SARS-CoV-2, both
136 in high-income settings [4,5,7-11] and low- and middle-income settings, including in
137 neighbouring Kenya [3]. The principal advantage of sampling pregnant women is that they

138 remain one of the few patient groups for whom health services cannot be postponed until after
139 the pandemic has passed. They are permitted and encouraged to attend even in the face of social
140 and movement restrictions, and so provide a consistent and reliable sampling group. The
141 principal limitation of this group is their restriction on age and sex, however, in most settings,
142 including other East African countries, seroprevalence does not vary significantly by sex and the
143 cumulative incidence in women is likely to represent the infection history of both sexes [12].
144 Similarly, in most settings young adults are the group most likely to be infected by SARS-CoV-2
145 and so the seroprevalence estimates here are likely to represent the highest risk in the whole
146 population; other age groups, particularly children and the elderly, are likely to have lower
147 seroprevalence [13,14].

148 The World Health Organization has deprecated the use of rapid tests for SARS-CoV-2 antibodies
149 for individual diagnosis but recognises their potential value in research [15]. WHO has also
150 recommended and endorsed quantitative analysis of IgG antibodies using ELISA and has
151 distributed the WANTAI ELISA kit to countries undertaking serosurveillance. Reliance on
152 ELISA, however, limits the range of settings in which serosurveillance can be undertaken and
153 lateral flow tests have been successfully employed for recurrent community-based nationwide
154 surveys in the UK [16]. When seroprevalence is low, as at the beginning of our study, an assay
155 with imperfect specificity may detect more false positives than true positives. The specificity of
156 the WANTAI rapid test has been estimated by the manufacturer at 98.8%. We assayed 80
157 samples each month in April and May 2020 without observing a single positive test, suggesting
158 that the specificity is indeed very high. Even if the positive results identified in June included
159 false positives, the progressive rise in seropositivity with time is most unlikely to be influenced
160 materially by a small fraction of false positive results.

161 The assay sensitivity may also be imperfect in detecting prior infection because the assay was
162 originally calibrated against sera from symptomatic cases, who generally have higher antibody
163 levels than asymptomatic individuals [17], and because pregnant women who were infected
164 several months ago may have experienced waning of antibody levels and seroreversion [18-22].
165 In general, seroreversion is less problematic in assays that measure total immunoglobulin and in
166 those that target spike antigens, compared to nucleocapsid antigens [20,23], so problem of
167 waning in this study is unlikely to be substantial. Furthermore, if sensitivity is unlikely to decline
168 over time, imperfect sensitivity would not affect the shape of the rising seroprevalence line,
169 though it would underestimate the gradient. If, as estimated in one validation study, the
170 WANTAI rapid test has a sensitivity of only 89% [24], adjustment for test-performance
171 characteristics would elevate our reported seroprevalence results by a factor of 1.12.

172 The results are in contrast to most other settings studied which record a sharp take-off in
173 seroprevalence once transmission begins, often rising quickly to high levels. In Kenya for
174 example, women attending an ANC clinic in Kilifi had seroprevalence of 0%, 2% and 11% in
175 consecutive months September-November 2021; those attending ANC clinic in Nairobi had a
176 seroprevalence of 50% in August 2020 [3]. The pattern illustrated in eastern Ethiopia is more
177 indicative of a gradually spreading epidemic curve suggesting an effective reproduction number
178 much closer to 1.

179 In Juba, South Sudan, seroprevalence was 22% in a household survey in August-September 2020
180 [25]; in Kenya, a national estimate for seroprevalence, based on testing blood transfusion donors,
181 was 4.3% in May 2020 [12] and 9.1% two months later [26]. Health Care Workers in Nairobi,
182 Kenya, had a seroprevalence of 44% in August 2020; those in two rural hospitals had

183 seroprevalence of 12-13% in November 2020 [27]. Finally, in Addis Ababa seroprevalence,
184 estimated in May 2020, was 3.0% [28]. Although all these studies used different laboratory
185 assays and varied statistical adjustments, collectively, they suggest that transmission in eastern
186 Ethiopia began later than in much of the rest of the region, including the state capital, and has
187 progressed more slowly.

188 In summary if seroprevalence is a reliable indicator of cumulative incidence, SARS-CoV-2
189 infection is spreading slowly but steadily in eastern Ethiopia. This contrasts sharply with the
190 recurrent waves of PCR-positive infections apparent in the national surveillance system. One
191 year after the start of the epidemic approximately 10% of women attending ante-natal clinics are
192 seropositive implying that the COVID-19 epidemic is still at an early stage in eastern Ethiopia.

193 **Material and methods**

194 **Study area and period**

195 The surveillance was conducted between April 1, 2020 and March 31, 2021 at Aweday Health
196 Centre and Haramaya District Hospital, both in Haramaya District, and in Hiwot Fana
197 Specialized Referral University Hospital in Harar. Hiwot Fana is the largest referral and teaching
198 hospital in eastern Ethiopia and receives tertiary referrals from Harari region, East Oromia,
199 Somali region, and Dire Dawa City. It is one of the ten regional centres designated by the
200 Federal Ministry of Health to manage the COVID-19 epidemic. Haramaya Hospital was rapidly
201 designated a COVID-19 treatment facility and women seeking ANC services were therefore
202 referred to Aweday Health Centre after April 16, 2020.

203 **Study design, population and sample size**

204 At the end of March 2020, we integrated Health facility-based surveillance into the routine
205 clinical care of pregnant women at Hiwot Fana Hospital, Aweday Health Centre and Haramaya
206 Hospital. The study population comprised 3306 pregnant women attending their first antenatal
207 care in these three facilities during the surveillance period. A total 78 women were excluded
208 because they were not willing to provide blood sample. Routine antenatal care includes
209 serological screening for HIV, syphilis, and toxoplasma infection during pregnancy undertaken
210 in two blood samples; the first blood sample is taken at 16 weeks' gestation or at the first ANC
211 visit, if later.

212 Socio-demographic data and information on pregnancy, clinical symptoms of COVID-19 and co-
213 morbidities was collected by trained nurses. COVID-19 symptoms were defined as at least one
214 of cough, fever, headache or difficulty breathing. Data quality and completeness were checked
215 daily.

216 **Laboratory analyses**

217 For the anti-SARS-CoV-2 antibodies test, residual blood samples from the routine ANC tests
218 were transferred to a test-tube containing clot activator by trained medical laboratory
219 technologists working in each health facility. The blood samples were allowed to clot and serum
220 was separated by centrifugation at 3000 RPM for 10 minutes. Serum samples were stored at 2-
221 8°C at each site and transported in cool boxes to Hararghe Health Research Laboratory where
222 they were stored at -80°C.

223 Samples were tested using WANTAI® SARS-CoV-2 Ab Rapid Test. The test is a lateral flow
224 assay in a cassette format designed for the qualitative detection of total antibodies to SARS-
225 CoV-2 in human serum. The receptor-binding domain of the SARS-CoV-2 spike protein is
226 bound at the Test Zone (T) and antibodies are bound at the Control Zone (C) of the cassette. The
227 test has a sensitivity of 100% and specificity of 98.8% under validation performed by the
228 manufacturer; independent validation of the test found a sensitivity of 89% [24]. All the stored
229 serum samples, tests reagents and cassettes were brought to room temperature (15-30°C) thirty
230 minutes before performing the test; 10µl of serum specimen and two drops of diluent buffer were
231 added into the specimen window. Results were read and interpreted as reactive/positive (Red line
232 on C and T) or non-reactive/negative (Red line on C) after 15-20 minutes [24,29]. Serum
233 samples taken ≥ 14 days after a positive PCR test from COVID-19 infected individuals were used
234 as quality control.

235 **Statistical analysis**

236 We used STATA version 16.0 for statistical analysis. We estimated unadjusted seroprevalence of
237 SARS-CoV-2 IgG antibody with a 95% confidence interval (CI). We did not make adjustment
238 for the test performance characteristics because the manufacturer's validation assay, found very
239 high sensitivity and specificity. We examined the univariate association between individual
240 characteristics and seropositivity using χ^2 and multivariable associations using binomial
241 regression. The trend in seropositivity with time was tested with a χ^2 test for trend and in the
242 multivariable model.

243 **Ethical consideration**

244 The study was confined to residual clinical blood sample testing and anonymized questionnaire
245 data. It was conducted as part of a public health surveillance, with the approval of the director of
246 each of the three health facilities and the data were made available to relevant bodies including
247 the Regional Health Bureau (Harari and Oromia) and the Ethiopian Public Health Institute
248 (EPHI). Ethical clearance was secured from Institutional Health Research Ethical Review
249 Committee of the College of Health and Medical Sciences, Haramaya University, Ethiopia.

250 **Data availability**

251 Data is available in the following link and can be requested using the form in the link.
252 <https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/XIWCXN>.

253 **Acknowledgements**

254 Activities of the surveillance and Laboratory analysis was supported by Emory University as part
255 of the CHAMPS network (www.champshealth.org). JAGS was funded by The Wellcome Trust
256 through a Senior Research Fellowship (214320).

257 **Author contribution**

258 NA and JAGS lead overall Surveillance. NA, JAGS, ZT and LDR develop concept of the
259 Surveillance, analyzed the data and wrote the manuscript. ZT provided microbiome data
260 analysis, and interpretation. NA, JAGS, ZT, LDR, LM, JO and YD reviewed the manuscript and
261 give critical feedback. All authors approved the submission of the manuscript to the journal.

262 **Competing of interest**

263 The authors declare no competing interests.

264

265

266 **References**

- 267 1 Abdela, S. G. *et al.* Clinical Profile and Treatment of COVID-19 Patients: Experiences
268 from an Ethiopian Treatment Center. *Am J Trop Med Hyg*, doi:10.4269/ajtmh.20-1356
269 (2020).
- 270 2 Abraha, H. E. *et al.* Clinical features and risk factors associated with morbidity and
271 mortality among patients with COVID-19 in northern Ethiopia. *Int J Infect Dis* **105**, 776-
272 783, doi:10.1016/j.ijid.2021.03.037 (2021).
- 273 3 Lucinde, R. *et al.* Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two
274 Kenyan referral hospital. *medRxiv submitted* (2021).
- 275 4 Lumley, S. F. *et al.* SARS-CoV-2 antibody prevalence, titres and neutralising activity in an
276 antenatal cohort, United Kingdom, 14 April to 15 June 2020. *Euro Surveill* **25**,
277 doi:10.2807/1560-7917.ES.2020.25.41.2001721 (2020).
- 278 5 Villalaín, C. *et al.* Seroprevalence analysis of SARS-CoV-2 in pregnant women along the
279 first pandemic outbreak and perinatal outcome. *PLOS ONE* **15**, e0243029,
280 doi:10.1371/journal.pone.0243029 (2020).
- 281 6 Kigadye, R. M. *et al.* Sentinel surveillance for HIV-1 among pregnant women in a
282 developing country: 3 years' experience and comparison with a population serosurvey.
283 *AIDS* **7**, 849-855, doi:10.1097/00002030-199306000-00014 (1993).
- 284 7 Cosma, S. *et al.* The "scar" of a pandemic: Cumulative incidence of COVID-19 during the
285 first trimester of pregnancy. *J Med Virol* **93**, 537-540, doi:10.1002/jmv.26267 (2021).
- 286 8 Crovetto, F. *et al.* Seroprevalence and presentation of SARS-CoV-2 in pregnancy. *Lancet*
287 **396**, 530-531, doi:10.1016/S0140-6736(20)31714-1 (2020).
- 288 9 Flannery, D. D. *et al.* SARS-CoV-2 seroprevalence among parturient women in
289 Philadelphia. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abd5709 (2020).
- 290 10 Haizler-Cohen, L., Davidov, A., Blitz, M. J. & Fruhman, G. Severe acute respiratory
291 syndrome coronavirus 2 antibodies in pregnant women admitted to labor and delivery
292 units. *Am J Obstet Gynecol* **224**, 112-114, doi:10.1016/j.ajog.2020.09.022 (2021).
- 293 11 Mattern, J. *et al.* Post lockdown COVID-19 seroprevalence and circulation at the time of
294 delivery, France. *PLoS One* **15**, e0240782, doi:10.1371/journal.pone.0240782 (2020).
- 295 12 Uyoga, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood
296 donors. *Science* **371**, 79-82, doi:10.1126/science.abe1916 (2021).

- 297 13 Murhekar, M. V. *et al.* SARS-CoV-2 antibody seroprevalence in India, August-September,
298 2020: findings from the second nationwide household serosurvey. *Lancet Glob Health* **9**,
299 e257-e266, doi:10.1016/S2214-109X(20)30544-1 (2021).
- 300 14 Pollan, M. *et al.* Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,
301 population-based seroepidemiological study. *Lancet* **396**, 535-544, doi:10.1016/S0140-
302 6736(20)31483-5 (2020).
- 303 15 World Health Organization. [https://www.who.int/news-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)
304 [room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)
305 [for-covid-19](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19) (2020).
- 306 16 Moshe, M. *et al.* SARS-CoV-2 lateral flow assays for possible use in national covid-19
307 seroprevalence surveys (React 2): diagnostic accuracy study. *BMJ* **372**, n423,
308 doi:10.1136/bmj.n423 (2021).
- 309 17 Takahashi, S., Greenhouse, B. & Rodriguez-Barraquer, I. Are Seroprevalence Estimates
310 for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? *J Infect Dis* **222**, 1772-
311 1775, doi:10.1093/infdis/jiaa523 (2020).
- 312 18 Ibarondo, F. J. *et al.* Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild
313 Covid-19. *N Engl J Med* **383**, 1085-1087, doi:10.1056/NEJMc2025179 (2020).
- 314 19 Long, Q. X. *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2
315 infections. *Nat Med* **26**, 1200-1204, doi:10.1038/s41591-020-0965-6 (2020).
- 316 20 Lumley, S. F. *et al.* The duration, dynamics and determinants of SARS-CoV-2 antibody
317 responses in individual healthcare workers. *Clin Infect Dis*, doi:10.1093/cid/ciab004
318 (2021).
- 319 21 Muecksch, F. *et al.* Longitudinal Serological Analysis and Neutralizing Antibody Levels in
320 Coronavirus Disease 2019 Convalescent Patients. *J Infect Dis* **223**, 389-398,
321 doi:10.1093/infdis/jiaa659 (2021).
- 322 22 Ward, H. *et al.* Prevalence of antibody positivity to SARS-CoV-2 following the first peak
323 of infection in England: Serial cross-sectional studies of 365,000 adults. *Lancet Reg*
324 *Health Eur* **4**, 100098, doi:10.1016/j.lanep.2021.100098 (2021).
- 325 23 Post, N. *et al.* Antibody response to SARS-CoV-2 infection in humans: A systematic
326 review. *PLoS One* **15**, e0244126, doi:10.1371/journal.pone.0244126 (2020).

- 327 24 Weidner, L. *et al.* Quantification of SARS-CoV-2 antibodies with eight commercially
328 available immunoassays. *Journal of Clinical Virology* **129**, 104540,
329 doi:<https://doi.org/10.1016/j.jcv.2020.104540> (2020).
- 330 25 Wiens, K. E. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South
331 Sudan: a population-based study. *medRxiv*, doi:10.1101/2021.03.08.21253009 (2021).
- 332 26 Adetifa, I. M. O. *et al.* Temporal trends of SARS-CoV-2 seroprevalence in transfusion
333 blood donors during the first wave of the COVID-19 epidemic in Kenya. *medRxiv*,
334 doi:<https://www.medrxiv.org/content/10.1101/2021.02.09.21251404v1> (2021).
- 335 27 Etyang, A. O. *et al.* Seroprevalence of Antibodies to SARS-CoV-2 among Health Care
336 Workers in Kenya. *Clin Infect Dis*, doi:10.1093/cid/ciab346 (2021).
- 337 28 Kempen, J. H. *et al.* SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia. *Am J Trop Med*
338 *Hyg* **103**, 2022-2023, doi:10.4269/ajtmh.20-0816 (2020).
- 339 29 The WANTAI SARS-CoV-2 Ab Rapid Test. *Beijing Wantai Biological Pharmacy*
340 *Enterprise Co., Ltd. No.31* <www.ystwt.com> (2020).

341

342